All News Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-25 am EDT			5-day change	1st Jan Change
2,331 ^INR	0.00%		+3.97%	-9.46%

Mar. 18	Dr Lal Pathlabs Names CEO	MT
Mar. 17	Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dr Lal Pathlabs Names CEO	Mar. 17	MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	Mar. 16	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer	Mar. 03	CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral	Feb. 05	MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	Feb. 01	MT
Dr. Lal PathLabs Seeks M&A	Feb. 01	CI
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024	Feb. 01
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	Feb. 01	RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	Feb. 01	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 01	CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	Jan. 25	MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002	Nov. 06	MT
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5%	Nov. 03	MT
Transcript : Dr. Lal PathLabs Limited, H1 2024 Earnings Call, Nov 02, 2023	Nov. 02
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 02	CI
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023	23-09-12	CI
Dr. Lal PathLabs Limited Announces Change in Directorate	23-08-20	CI
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q1; Revenue Meets Estimates	23-07-31	MT
Nomura Downgrades Dr. Lal Pathlabs to Reduce From Neutral, Adjusts Price Target to INR2,002 From INR1,835	23-07-31	MT
Dr. Lal PathLabs Seeks Inorganic Opportunity	23-07-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

All News

Filters